Foreword: Uterine Transplantation in Pregnancy
No abstract available (Source: Clinical Obstetrics and Gynecology)
Source: Clinical Obstetrics and Gynecology - January 29, 2022 Category: OBGYN Tags: Uterine Transplantation in Pregnancy Source Type: research
Contributors: Uterine Transplantation in Pregnancy
No abstract available (Source: Clinical Obstetrics and Gynecology)
Source: Clinical Obstetrics and Gynecology - January 29, 2022 Category: OBGYN Tags: Contributors: Uterine Transplantation in Pregnancy Source Type: research
Index
No abstract available (Source: Clinical Obstetrics and Gynecology)
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Index Source Type: research
Ethical, Legal, and Social Implications of Fetal Gene Therapy
As fetal gene therapies move from experimental animal models to human in utero phase I clinical trials, there is a need to consider the ethical, legal, and social implications. While fetal gene therapies are attracting more regulatory oversight than previous fetal interventions such as fetal surgery, old sociological questions should be applied to this new context. As health care pathways around fetal therapy are shaped by the ways in which a pregnant person and the fetus are constituted, and as risks and benefits are evaluated, we cannot afford to lose sight of long-term consequences, especially those pertaining to social...
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Gene Therapy in Obstetrics Source Type: research
The Current State and Future of Fetal Therapies
This article reviews emerging fetal therapies, as well as existing guidance for their development, considerations for their safety, and ethical and societal implications. (Source: Clinical Obstetrics and Gynecology)
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Gene Therapy in Obstetrics Source Type: research
Spinal Muscular Atrophy: A Potential Target for In Utero Therapy
Spinal muscular atrophy (SMA) is a life-threatening autosomal recessive disease that leads to progressive muscle weakness and atrophy, respiratory insufficiency and scoliosis. SMA is currently the most common monogenic cause of infant mortality. Amazing advancements have been made in the therapeutic options available for these children since 2016. What has also become clear is that the earlier the treatment is administered, the better the clinical outcome. For several reasons, which we will review in this chapter, SMA may be an excellent disease candidate for in utero therapy. (Source: Clinical Obstetrics and Gynecology)
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Gene Therapy in Obstetrics Source Type: research
Prenatal Gene Therapy for Metabolic Disorders
Gene therapy has traditionally involved the delivery of exogenous genetic material to a cell—most commonly to replace defective genes causing monogenic disorders. This allows cells to produce proteins that are otherwise absent in sufficient quantities, ideally for a therapeutic purpose. Since its inception over 40 years ago, the field of gene therapy has significantly expanded and now includes targeted gene editing strategies, including, but not limited to, clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), transcription activator–like effector nucleases (TALENs), and zinc-...
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Gene Therapy in Obstetrics Source Type: research
Mesenchymal Stem Cell Therapy for Osteogenesis Imperfecta
The aim of this study was to provide a brief overview on the background and rationale on treating fetuses and children suffering from osteogenesis imperfecta (OI) with mesenchymal stem cells (MSCs). MSCs ability to migrate, engraft, and differentiate into bone cells and to act via paracrine effects on the recipient’s tissues makes these cells promising candidates as a clinical therapy for OI. Animal work and limited clinical studies in humans support the use of MSC in treating OI. Off-the-shelf MSC have a good safety profile and exhibit multilineage differentiation potential and a low immunogenic profile and thereby may ...
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Gene Therapy in Obstetrics Source Type: research
In Utero Gene Therapy for Primary Immunodeficiencies
Primary immunodeficiencies (PIDs) have become a prime target for gene therapy given the morbidity, mortality, and the single gene etiology. Given that outcomes are better the earlier gene therapy is implemented, it is possible that fetal gene therapy may be an important future direction for the treatment of PIDs. In this chapter, the current treatments available for several PIDs will be reviewed, as well as the history and current status of gene therapy for PIDs. The possibility of in utero gene therapy as a possibility will then be discussed. (Source: Clinical Obstetrics and Gynecology)
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Gene Therapy in Obstetrics Source Type: research
Prenatal Gene Therapy
Prenatal gene therapy could provide a cure for many monogenic diseases. Prenatal gene therapy has multiple potential advantages over postnatal therapy, including treating before the onset of disease, the ability to induce tolerance and cross the blood-brain barrier. In this chapter, we will describe in utero gene therapy and its rationale, clinical trials of postnatal gene therapy, preclinical studies of in utero gene therapy, and potential risks to the mother and fetus. (Source: Clinical Obstetrics and Gynecology)
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Gene Therapy in Obstetrics Source Type: research
In Utero Fetal Therapy: Stem Cells, Cell Transplantation, Gene Therapy, and CRISPR-Cas9
In utero fetal therapy offers the opportunity to prevent and treat diseases with a cellular or genetic basis. Components of successful fetal treatment include isolation of a replacement cell population, in utero stem cell transplantation, cell engraftment with fetal immune tolerance, and ongoing cell function. Fetal gene therapy with CRISPR-Cas9 represents an exciting potential therapy for genetic diseases not amenable to gene supplementation via adenoviral vector transduction. These fetal therapies have unique ethical and safety considerations. Clinical trials for in utero cell therapy are underway, as additional discover...
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Gene Therapy in Obstetrics Source Type: research
An Introduction: Prenatal Screening, Diagnosis, and Treatment of Single Gene Disorders
Increasing ability to diagnose fetal single gene disorders has changed the prenatal diagnostic paradigm. As fetal sequencing advances, the genomic information obtained can lead to improved prognostic counseling, and elucidation of recurrence risk and future prenatal diagnosis options. For some of these disorders, postnatal molecular therapy, including gene therapy, is available or being studied in clinical trials. Most of the initial research and clinical trials have involved children and adults, but there are potential benefits to treating conditions before birth. Many clinical studies are underway exploring the potential...
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Gene Therapy in Obstetrics Source Type: research
Foreword: Gene Therapy in Obstetrics
No abstract available (Source: Clinical Obstetrics and Gynecology)
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Gene Therapy in Obstetrics Source Type: research
Contributors: Gene Therapy in Obstetrics
No abstract available (Source: Clinical Obstetrics and Gynecology)
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Contributors: Gene Therapy in Obstetrics Source Type: research
Eliminating Hormones With Orally Active Gonadotropin-releasing Hormone Antagonists
Gonadotropin-releasing hormone (GnRH) analogues have been used in clinical practice for nearly 3 decades. Beginning with GnRH agonists, these agents have been used to treat hormone-dependent disease and to suppress gonadotropin production in assisted reproductive technologies. With the development of GnRH antagonists and especially small-molecule antagonists, our ability to achieve gonadotropin and sex steroid suppression has become increasingly effective and convenient. In this review, we will briefly describe the development of GnRH analogues, review the evolution of orally active small-molecule GnRH antagonists and prov...
Source: Clinical Obstetrics and Gynecology - October 21, 2021 Category: OBGYN Tags: Hormone Use in Gynecology Source Type: research
